The correlation between electronic structure and antitumor activity of a seletive focal adhesion kinase inhibitors
Article Sidebar
Main Article Content
Abstract
Focal Adhesion Kinase (FAK) is a non-tyrosine kinase responsible to phosphorylate other enzymes associated with signal transduction. This biochemical process plays an important role to control cancer. FAK is found overexpressed in the organism during metastasis. Since FAK may be involved in the invasion and metastasis of cancer, novel molecules based on drug design have been synthesized over the past few years. The inhibitors are designed to mimic the natural substrate which is the ATP molecule. This work studied the hydrogen bonds performed between inhibitors and FAK and other electronic properties involved in this interaction. The molecular structure of FAK docked with the inhibitors was simulated using classical molecular dynamics. FAK/ inhibitor complex obtained by dynamic was optimized using quantum mechanical ab-initio calculation. Our results show that all inhibitors interact with Cys502 located in the FAK-binding site. Ab-initio calculations show that HOMO orbital is situated under Met499 and Glu500 amino acids indicating chemical reactivity in this region. The results of molecular dynamics combined with quantum chemical calculations show that the sulfonamide has a strong hydrogen bond with close distances, while the thiazole has a weak hydrogen bond with long distances. Sulfonamide has known good activity against FAK while the thiazole molecule has an unknown activity. These results allow predicting that the molecule of thiazole is a not good inhibitor to FAK inhibition.
Metrics
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
The corresponding author transfers the copyright of the submitted manuscript and all its versions to Eclet. Quim., after having the consent of all authors, which ceases if the manuscript is rejected or withdrawn during the review process.
When a published manuscript in EQJ is also published in other journal, it will be immediately withdrawn from EQ and the authors informed of the Editor decision.
Self-archive to institutional, thematic repositories or personal webpage is permitted just after publication. The articles published by Eclet. Quim. are licensed under the Creative Commons Attribution 4.0 International License.
References
McCubrey, J. A., Abrams, S. L., Stadelman, K., Chappell, W. H., LaHair, M., Ferland, R. A., Steelman, L. S., Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells, Adv. Enzyme Regu. 50 (2010) 285-307. https://doi.org/10.1016/j.advenzreg.2009.10.016.
Collins, I., Workman, P., Design and development of signal transduction inhibitors for cancer treatment: Experience and challenges with kinase targets, Current Signal Transduction Therapy 1 (1) (2006) 13-23. https://doi.org/10.2174/157436206775269181.
Fulda, S., Debatin, K.-M., Signal transduction therapy targeting apoptosis pathways in cancers, Current Signal Transduction Therapy 1 (2) (2006) 179-190. https://doi.org/10.2174/157436206777012075.
Klein, S., Levitzki, A., Signal transduction therapy for cancer - Whither now? Current Signal Transduction Therapy 1 (1) (2006) 1-12. https://doi.org/10.2174/157436206775269244.
Christoffersen, T., Guren, T. K., Spindler, K.-L. G., Dahl, O., Lonning, P. E., Gjertsen, B. T., Cancer therapy targeted at cellular signal transduction mechanisms: Strategies, clinical results, and unresolved issues, European Journal of Pharmacology 625 (2009) 6-22. https://doi.org/10.1016/j.ejphar.2009.10.009.
Bidwell, G. L. III, Raucher, D., Therapeutic peptides for cancer therapy. Part I - peptide inhibitors of signal transduction cascades, Expert Opinion on Drug Delivery 6 (10) (2009) 1033-1047. https://doi.org/10.1517/17425240903143745.
Levitzki, A., Klein, S., Signal transduction therapy of cancer, Molecular Aspects of Medicine 31 (4) (2010) 287-329. https://doi.org/10.1016/j.mam.2010.04.001.
Huang, S.-M., Hsu, P.-C., Chen, M.-Y., Li, W.-S., More, S. V., Lu, K.-T., Wang, Y.-C., The novel indole compound SK228 induces apoptosis and FAK/Paxillin disruption in tumor cell lines and inhibits growth of tumor graft in the nude mouse, International Journal of Cancer 131 (2012) 722-732. https://doi.org/10.1002/ijc.26401.
Chang, S. K., Hindes, A., Cornelius, L. A., Efimova, T., Proline-rich tyrosine kinase 2 (Pyk2), a focal adhesion kinase (FAK) homologue, induces apoptosis in human malignant metastatic melanoma, Journal of Investigative Dermatology 132 (2012) 130-130. https://doi.org/10.2353/ajpath.2008.080292.
Kwak, S. W., Park, E. S., Lee, C. S., Parthenolide induces apoptosis by activating the mitochondrial and death receptor pathways and inhibits FAK-mediated cell invasion, Molecular and Cellular Biochemistry 385 (2014) 133-144. https://doi.org/10.1007/s11010-013-1822-4.
Shieh, J.-M., Wei, T.-T., Tang, Y.-A., Huang, S.-M., Wen, W.-L., Chen, M.-Y., Cheng, H.-C., Salunke, S. B., Chen, C.-S., Lin, P., Chen, C.-T., Wang, Y.-C., Mitochondrial Apoptosis and FAK Signaling Disruption by a Novel Histone Deacetylase Inhibitor, HTPB, in Antitumor and Antimetastatic Mouse Models, Plos One 7 (1) (2012) e30240. https://doi.org/10.1371/journal.pone.0030240.
Yoon, H., Choi, Y.-L., Song, J.-Y., Do, I., Kang, S. Y., Ko, Y.-H., Song, S., Kim, B.-G., Targeted Inhibition of FAK, PYK2 and BCL-XL Synergistically Enhances Apoptosis in Ovarian Clear Cell Carcinoma Cell Lines, Plos One 9 (2) (2014) e88587. https://doi.org/10.1371/journal.pone.0088587.
Vanamala, J., Radhakrishnan, S., Reddivari, L., Bhat, V. B., Ptitsyn, A., Resveratrol suppresses human colon cancer cell proliferation and induces apoptosis via targeting the pentose phosphate and the talin-FAK signaling pathways-A proteomic approach, Proteome Science 9 (1) (2011) 49. https://doi.org/10.1186/1477-5956-9-49.
Kanteti, R., Mirzapoiazova, T., Riehm, J. J., Dhanasingh, I., Mambetsariev, B., Wang, J., Kulkarni, P., Kaushik, G., Seshacharyulu, P., Ponnusamy, M. P., Kindler, H. L., Nasser, M. W., Batra, S. K., Salgia, R., Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma, Cancer Biology Therapy 19 (4) (2018) 316-327. https://doi.org/10.1080/15384047.2017.1416937.
Roberts, W. G., Ung, E., Whalen, P., Cooper, B., Hulford, C., Autry, C., Richter, D., Emerson, E., Lin, J., Kath, J., Coleman, K., Yao, L., Martinez-Alsina, L., Lorenzen, M., Berliner, M., Luzzio, M., Patel, N., Schmitt, E., LaGreca, S., Jani, J., Wessel, M., Marr, E., Griffor, M., Vajdos, F., Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271, Cancer R. 15 (2008) 1935-1944. https://doi.org/10.1158/0008-5472.CAN-07-5155.
Koolman, H., Heinrich, T., Musil, D., Co-crystal Structures of FAK with an Unprecedented Pyrrolo[2,3-d]thiazole, Accessed in June 2017 https://www.rcsb.org/structure/3pxk.
Barra de Oliveira, D. A., de Oliveira Neto, M., Martins, J. B. L., Theoretical study of disubstituted pyrrolopyrimidines as focal adhesion kinase inhibitors, International Journal of Quantum Chemistry 10 (2012) 2324-2329. https://doi.org/10.1002/qua.23181.
Andersen, C. B., Ng, K., Ficarro, S., Vu, C., Choi, H.-S., He, Y., Spraggon, G., Gray, N., Lee, C. C., Crystal Structure of Focal Adhesion Kinase Catalytic Domain Complexed with ATP and Novel 7H-Pyrrolo [2,3-d] pyrimidine Inhibitor Scaffolds, Accessed in June 2017. https://www.rcsb.org/structure/2ijm.
HyperChem(TM) Professional 7.51, Hypercube, Inc., 1115 NW 4th Street, Gainesville, Florida 32601, USA.
Brooks, B. R., Bruccoleri, R. E., Olafson, B. D., States, D. J., Swaminathan, S., Karplus, M. "CHARMM: A program for macromolecular energy, minimization, and dynamics calculations", J. Comp. Chem. 4 (2) (1983) 187–217. https://doi.org/10.1002/jcc.540040211.
Zoete, V., Cuendet, M. A., Grosdidier, A., Michielin, O., SwissParam: A Fast Force Field Generation Tool For Small Organic Molecules, J. Comput. Chem. 32 (11) (2011) 2359-68. PMID: 21541964. https://doi.org/10.1002/jcc.21816.
Dapprich, S., Komáromi, I., Byun, K. S., Morokuma, K., Frisch, M. J., A New ONIOM Implementation in Gaussian 98. Part 1. The Calculation of Energies, Gradients and Vibrational Frequencies and Electric Field Derivatives, J. Mol. Struct. (Theochem) 462 (1999) 1-21. https://doi.org/10.1016/S0166-1280(98)00475-8.
Vreven T., Morokuma, K., Hybrid Methods: ONIOM(QM:MM) and QM/MM, Annual Reports in Comp. Chem. 2 (2006) 35-51. https://doi.org/10.1016/S1574-1400(06)02003-2.
Vreven, T., Byun, K. S., Komaromi, I., Dapprich, S., Montgomery Jr., J.A., Morokuma, K., Frisch, M. J., Combining Quantum Mechanics Methods with Molecular Mechanics Methods in ONIOM, J. of Chem. Theory and Computation 2 (3) (2006) 815-826. https://doi.org/10.1021/ct050289g.
Vreven, T., Frisch, M. J., Kudin, K. N., Schlegel, H. B., Morokuma, K., Geometry optimization with QM/MM Methods. II. Explicit Quadratic Coupling, Mol. Phys., 104 (2006) 701-714. https://doi.org/10.1080/00268970500417846.
Rappé, A. K., Goddard III, W. A., “Charge equilibration for molecular-dynamics simulations,” J. Phys. Chem. 95 (1991) 3358-3363. https://doi.org/10.1021/j100161a070.
Rappé, A. K., Casewit, C. J., Colwell, K. S., Goddard III, W. A., Skiff, W. M., UFF, a Full Periodic Table Force Field for Molecular Mechanics and Molecular Dynamics Simulations, J. Am. Chem. Soc. 114 (1992) 10024–10035. 0002-786319211514-10024%03.00/0.